News

We are always delighted to receive feedback directly from our clients. This recent email made our entire week!

Target Health is very pleased that it has prepared, submitted and obtained over 20 orphan drug designations, with 3 of these products reaching the market. There were 2 additional orphan programs in which Target Health played a major role.

Drug-resistant tuberculosis threatens recent gains in the treatment of tuberculosis and human immunodeficiency virus (HIV) infection worldwide.

Synthetic chemicals commonly found in insecticides and garden products bind to the receptors that govern our biological clocks researchers have found.

Target e*CTR® (eClinical Trial Record) is Target Health’s patented eSource solution fully integrated with Target e*CRF®. A de novo 510(k) was cleared in December 2015 that used direct data entry at the time of the office visit, and an NDA was submitted to FDA with 7 studies which all used Target e*CTR. There were no FDA inspection findings in any of these programs.

The timing of the first entry of humans into North America across the Bering Strait has now been set back 10,000 years, scientists report.

On 4 January 2017, Applied Clinical Trials published an online paper, entitled, “Regulatory Considerations when Designing and Running 21st Century Paperless Clinical Trials.“ The paper is coauthored by Jonathan Helfgott, MS, former the Associate Director for Risk Science at FDA CDER OSI and the main author of FDA’s eSource Guidance, and Jules Mitchel, MBA, PhD, President, Target Health Inc. Jonathan is currently the Coordinator of the Regulatory Science Graduate Program at Johns Hopkins University.

Even before they are born, premature babies may display alterations in the circuitry of their developing brains, according to a first-of-its kind research study.

A UC San Francisco-led study has identified signatures of ethnicity in the genome that appear to reflect an ethnic group’s shared culture and environment, rather than their common genetic ancestry.

As part of the continuing growth of Target Health Inc. we welcome Dave Luke, PharmD, FACA, FCCP, as Sr. Director of Clinical and Scientific Affairs. Dave will work closely with all departments at Target Health to provide both clinical, scientific and leadership support for all of our programs.